Redeye return with a research update following BioArctic's Q4 report and recent events, including th...
Raketech’s Q4-results were in line with the preannouncement from February 4 where the company report...
Marimekko's fourth quarter revenue beat our estimates slightly due to strong development in Finland.
External manufacturing and Artscape raise growth to 6% y-o-y DTC grew 100% y-o-y in 2024, more to co...
Sales -5% vs. cons, adj. EBITA -33% vs. cons Enters Norway with Habberstad acquisition Acquisition o...
Vaisala’s 2024 ended on a strong note as was expected after January’s positive profit warning.
Redeye comments on Medivir's Q4 report of 2024. In the quarter, the phase IIa study of fostrox was c...
Redeye states CoinShares Q4 2024 report exceeded Redeye Research estimates (RRe) across all segments...
Redeye comments on Synact's Q4 report. Synact raised in total SEK65m from a combined rights and dire...
Redeye updates on Gentoo Media post Q4-results where we see continued growth potential in the coming...
Redeye comments on the evening’s news regarding Integrum’s strategic shift for accelerating OPRA com...
CirChem har publicerat bolagets delårsrapport för det fjärde kvartalet 2024.
Earnings growth to pick up in 2025 EBIT raised by 3% for 2025e 2025e-26e EV/EBIT of 4x with easy com...
Redeye gives a short comment on today’s news that IRLAB extends its runway following “extended and e...
Redeye notes that the underlying Q4 figures came in stronger than anticipated, primarily due to bett...
Net sales of SEK46m were in line with our estimates, while EBIT exceeded expectations by SEK10m.
Aspo’s Q4 figures weren’t yet great, even if they improved a bit y/y, as ESL particularly had to end...
Strong organic growth in Q4 at 18%, albeit 2% below ABGSCe Q4 adj.
Gentoo Media reported solid topline in Q4 while EBITDA was somewhat softer than expected, partly due...
Extended Fenja loan (SEK 55m) with new SEK 20m option New shareholder loan (SEK 22.
